Evidence map›Paper›PMID 41795671›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Tau PET overlap index correlation with neuropathological findings.

Seokbeen Lim, Jeyeon Lee, Paul H Min, Christina M Moloney, Carly T Mester, Sujala Ghatamaneni, Matthew L Senjem, Hugo Botha, David S Knopman, Stuart J McCarter and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Seokbeen LimDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-4142-3478
Jeyeon LeeDepartment of Biomedical Engineering, Hanyang University, Seoul, Republic of Korea.
Paul H MinDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Christina M MoloneyDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Carly T MesterDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
Sujala GhatamaneniDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Matthew L SenjemInformation Technology, Mayo Clinic, Rochester, Minnesota, USA.
Hugo BothaDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
David S KnopmanDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Stuart J McCarterDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Vijay K RamananDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Rodolfo SavicaDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Julie A FieldsDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.
Mary M MachuldaDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.
Dennis W DicksonLaboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida, USA.
R Ross ReichardLaboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Aivi T NguyenLaboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Christopher G SchwarzDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Jeffrey L GunterDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Kejal KantarciDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Bradley BoeveDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Prashanthi VemuriDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
David T JonesDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Melissa E MurrayDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Val J LoweDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-5612-1667

Funding

Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI Bradley F Boeve · 2019 to 2026
$120.9M
SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI PETERSEN, RONALD C · 1999 to 2018
$36.9M
Longitudinal Imaging Biomarkers of Prodromal DLBU01NS100620 · NINDS · MAYO CLINIC ROCHESTER · PI Bradley F Boeve, KEJAL KANTARCI · 2017 to 2026
$19.2M
Rochester Epidemiology ProjectR01AG034676 · NIA · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A, ST SAUVER, JENNIFER LYNN · 2010 to 2019
$9.5M
Investigating Resistance and Resilience Mechanisms in Alzheimer’s DiseaseR01AG056366 · NIA · MAYO CLINIC ROCHESTER · PI PRASHANTHI VEMURI · 2017 to 2026
$7.0M
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8M
Validating the New Criteria for Preclinical Alzheimer's diseaseR01AG041851 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R., KNOPMAN, DAVID S · 2012 to 2021
$6.3M
Protecting the Confidentiality of Participants in Studies of Alzheimer's Disease and Related Dementias by Replacing Face Imagery in MRIR01AG068206 · NIA · MAYO CLINIC ROCHESTER · PI SCHWARZ, CHRISTOPHER GEORGE · 2021 to 2024
$3.2M
Development, Validation, and Application of an Imaging based CVD ScaleR01NS097495 · NINDS · MAYO CLINIC ROCHESTER · PI VEMURI, PRASHANTHI · 2016 to 2020
$2.9M
"What is N?" Towards operationalizing neurodegeneration in Alzheimer's and related dementiasRF1AG069052 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, MIELKE, MICHELLE M · 2021 to 2021
$2.4M
Tau PET/CT for Early Detection of Alzheimer’s Disease PathologyR01AG073282 · NIA · MAYO CLINIC ROCHESTER · PI LOWE, VAL JOHN, MURRAY, MELISSA ERIN · 2021 to 2025
$2.0M
Elsie and Marvin Dekelboum Family FoundationGHR FoundationHanyang University HY-202400000003953Korean government RS-2023-00226494Liston Award Family FoundationMayo Foundation for Medical Education and ResearchNational Research FoundationNIH HHS P30 AG62677NIH HHS P50 AG016574NIH HHS R01 AG034676NIH HHS R01 AG041851NIH HHS R01 AG056366NIH HHS R01 AG068206NIH HHS R01 AG073282NIH HHS R01 NS097495NIH HHS R37 AG011378NIH HHS RF1 AG069052NIH HHS RO1 NS124337-02NIH HHS U01 AG006786NIH HHS U01 NS100620NIH HHS U19 AG063911The Alexander Family Alzheimer's Disease Research Professorship of the Mayo ClinicThe Robert H. and Clarice Smith and Abigail van Buren Alzheimer's Disease Research Program, The Schuler Foundation
6 · The paper itself

Abstract

introductionThe tau positron emission tomography (PET) overlap index (OI) has shown promise in maximizing signal-to-noise for longitudinal tau PET imaging, particularly for early tau pathology, but requires validation against neuropathology.

methodsFifty-seven participants who underwent serial tau PET imaging (flortaucipir) and subsequent autopsy were included. Tau PET OI and standardized uptake value ratios (SUVRs) were compared across neuropathological diagnoses.

resultsTau PET OI showed greater concordance with neurofibrillary tangle (NFT) severity in the entorhinal cortex (a key region for Alzheimer's disease [AD] tauopathy) than SUVR, particularly in early Braak tangle stages (positivity: 52.2% for OI vs. 13.0% for SUVR). OI detected overlapping tau voxels that exhibited spatial correspondence with immunohistochemical and autoradiography measures of tau deposition across both AD and non-AD tauopathies. DISCUSSION: These findings demonstrate the enhanced capacity of OI in serial tau PET to robustly detect early and spatially localized tau pathology, supporting its application as a sensitive imaging metric in AD and select non-AD tauopathies.

Indexed as

Alzheimer DiseaseBrainPositron-Emission TomographyTauopathiestau ProteinsAgedAged, 80 and overAutoradiographyFemaleHumansMaleNeurofibrillary TanglesMAPT protein, humantau Proteins18F‐flortaucipirAlzheimer's diseaseautoradiographyBraak tangle stagesimmunohistochemistryneuropathological diagnosistauopathytau positron emission tomographytau positron emission tomography imagingtau positron emission tomography overlap index

Identifiers

PMID41795671
PMCPMC12967651

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.